 | • レポートコード：MRC2-11QY03655 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はカンジダ症治療薬のグローバル市場について調査・分析したレポートです。種類別（ドキソルビシン、シスプラチン、7カルボプラチン、エトポシド、イホスファミド、シクロホスファミド、メトトレキサート、ビンクリスチン）市場規模、用途別（多専門病院、がん研究所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別カンジダ症治療薬の競争状況、市場シェア ・世界のカンジダ症治療薬市場：種類別市場規模 2015年-2020年（ドキソルビシン、シスプラチン、7カルボプラチン、エトポシド、イホスファミド、シクロホスファミド、メトトレキサート、ビンクリスチン） ・世界のカンジダ症治療薬市場：種類別市場規模予測 2021年-2026年（ドキソルビシン、シスプラチン、7カルボプラチン、エトポシド、イホスファミド、シクロホスファミド、メトトレキサート、ビンクリスチン） ・世界のカンジダ症治療薬市場：用途別市場規模 2015年-2020年（多専門病院、がん研究所、その他） ・世界のカンジダ症治療薬市場：用途別市場規模予測 2021年-2026年（多専門病院、がん研究所、その他） ・北米のカンジダ症治療薬市場分析：米国、カナダ ・ヨーロッパのカンジダ症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのカンジダ症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のカンジダ症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのカンジダ症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis AG、Amgen、F. Hoffmann-La Roche Ltd.、Bayer-Algeta、Merrion Pharmaceuticals Plc.、Ablynx、Genta Incorporated、Galapagos NV、Catena Pharmaceuticals Inc.、Digna Biotech S.L.、Medivir AB、Amura Holdings ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Candidiasis Therapeutics Market
The global Candidiasis Therapeutics market size is projected to reach US$ 3112 million by 2026, from US$ 3008 million in 2020, at a CAGR of 3.2%% during 2021-2026.
Global Candidiasis Therapeutics Scope and Market Size
Candidiasis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Candidiasis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Candidiasis Therapeutics market is segmented into
Doxorubicin
Cisplatin
7Carboplatin
Etoposide
Ifosfamide
Cyclophosphamide
Methotrexate
Vincristine
Segment by Application, the Candidiasis Therapeutics market is segmented into
Multispecialty Hospitals
Cancer Research Institutes
Others
Regional and Country-level Analysis
The Candidiasis Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Candidiasis Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Candidiasis Therapeutics Market Share Analysis
Candidiasis Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Candidiasis Therapeutics business, the date to enter into the Candidiasis Therapeutics market, Candidiasis Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Novartis AG
Amgen
F. Hoffmann-La Roche Ltd.
Bayer-Algeta
Merrion Pharmaceuticals Plc.
Ablynx
Genta Incorporated
Galapagos NV
Catena Pharmaceuticals Inc.
Digna Biotech S.L.
Medivir AB
Amura Holdings
1 Study Coverage
1.1 Candidiasis Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Candidiasis Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Candidiasis Therapeutics Market Size Growth Rate by Type
1.4.2 Doxorubicin
1.4.3 Cisplatin
1.4.4 7Carboplatin
1.4.5 Etoposide
1.4.6 Ifosfamide
1.4.7 Cyclophosphamide
1.4.8 Methotrexate
1.4.9 Vincristine
1.5 Market by Application
1.5.1 Global Candidiasis Therapeutics Market Size Growth Rate by Application
1.5.2 Multispecialty Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Candidiasis Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Candidiasis Therapeutics Revenue 2015-2026
2.1.2 Global Candidiasis Therapeutics Sales 2015-2026
2.2 Global Candidiasis Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Candidiasis Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Candidiasis Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Candidiasis Therapeutics Competitor Landscape by Players
3.1 Candidiasis Therapeutics Sales by Manufacturers
3.1.1 Candidiasis Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Candidiasis Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Candidiasis Therapeutics Revenue by Manufacturers
3.2.1 Candidiasis Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Candidiasis Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Candidiasis Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Candidiasis Therapeutics Revenue in 2019
3.2.5 Global Candidiasis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Candidiasis Therapeutics Price by Manufacturers
3.4 Candidiasis Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Candidiasis Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Candidiasis Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Candidiasis Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Candidiasis Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Candidiasis Therapeutics Sales by Type (2015-2020)
4.1.2 Global Candidiasis Therapeutics Revenue by Type (2015-2020)
4.1.3 Candidiasis Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Candidiasis Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Candidiasis Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Candidiasis Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Candidiasis Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Candidiasis Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Candidiasis Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Candidiasis Therapeutics Sales by Application (2015-2020)
5.1.2 Global Candidiasis Therapeutics Revenue by Application (2015-2020)
5.1.3 Candidiasis Therapeutics Price by Application (2015-2020)
5.2 Candidiasis Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Candidiasis Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Candidiasis Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Candidiasis Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Candidiasis Therapeutics by Country
6.1.1 North America Candidiasis Therapeutics Sales by Country
6.1.2 North America Candidiasis Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Candidiasis Therapeutics Market Facts & Figures by Type
6.3 North America Candidiasis Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Candidiasis Therapeutics by Country
7.1.1 Europe Candidiasis Therapeutics Sales by Country
7.1.2 Europe Candidiasis Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Candidiasis Therapeutics Market Facts & Figures by Type
7.3 Europe Candidiasis Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Candidiasis Therapeutics by Region
8.1.1 Asia Pacific Candidiasis Therapeutics Sales by Region
8.1.2 Asia Pacific Candidiasis Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Candidiasis Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Candidiasis Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Candidiasis Therapeutics by Country
9.1.1 Latin America Candidiasis Therapeutics Sales by Country
9.1.2 Latin America Candidiasis Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Candidiasis Therapeutics Market Facts & Figures by Type
9.3 Central & South America Candidiasis Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Candidiasis Therapeutics by Country
10.1.1 Middle East and Africa Candidiasis Therapeutics Sales by Country
10.1.2 Middle East and Africa Candidiasis Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Candidiasis Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Candidiasis Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Candidiasis Therapeutics Products Offered
11.1.5 Novartis AG Related Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Description and Business Overview
11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Amgen Candidiasis Therapeutics Products Offered
11.2.5 Amgen Related Developments
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.3.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.3.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Products Offered
11.3.5 F. Hoffmann-La Roche Ltd. Related Developments
11.4 Bayer-Algeta
11.4.1 Bayer-Algeta Corporation Information
11.4.2 Bayer-Algeta Description and Business Overview
11.4.3 Bayer-Algeta Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bayer-Algeta Candidiasis Therapeutics Products Offered
11.4.5 Bayer-Algeta Related Developments
11.5 Merrion Pharmaceuticals Plc.
11.5.1 Merrion Pharmaceuticals Plc. Corporation Information
11.5.2 Merrion Pharmaceuticals Plc. Description and Business Overview
11.5.3 Merrion Pharmaceuticals Plc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Products Offered
11.5.5 Merrion Pharmaceuticals Plc. Related Developments
11.6 Ablynx
11.6.1 Ablynx Corporation Information
11.6.2 Ablynx Description and Business Overview
11.6.3 Ablynx Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Ablynx Candidiasis Therapeutics Products Offered
11.6.5 Ablynx Related Developments
11.7 Genta Incorporated
11.7.1 Genta Incorporated Corporation Information
11.7.2 Genta Incorporated Description and Business Overview
11.7.3 Genta Incorporated Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Genta Incorporated Candidiasis Therapeutics Products Offered
11.7.5 Genta Incorporated Related Developments
11.8 Galapagos NV
11.8.1 Galapagos NV Corporation Information
11.8.2 Galapagos NV Description and Business Overview
11.8.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Galapagos NV Candidiasis Therapeutics Products Offered
11.8.5 Galapagos NV Related Developments
11.9 Catena Pharmaceuticals Inc.
11.9.1 Catena Pharmaceuticals Inc. Corporation Information
11.9.2 Catena Pharmaceuticals Inc. Description and Business Overview
11.9.3 Catena Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Catena Pharmaceuticals Inc. Candidiasis Therapeutics Products Offered
11.9.5 Catena Pharmaceuticals Inc. Related Developments
11.10 Digna Biotech S.L.
11.10.1 Digna Biotech S.L. Corporation Information
11.10.2 Digna Biotech S.L. Description and Business Overview
11.10.3 Digna Biotech S.L. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Digna Biotech S.L. Candidiasis Therapeutics Products Offered
11.10.5 Digna Biotech S.L. Related Developments
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Description and Business Overview
11.1.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Novartis AG Candidiasis Therapeutics Products Offered
11.1.5 Novartis AG Related Developments
11.12 Amura Holdings
11.12.1 Amura Holdings Corporation Information
11.12.2 Amura Holdings Description and Business Overview
11.12.3 Amura Holdings Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Amura Holdings Products Offered
11.12.5 Amura Holdings Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Candidiasis Therapeutics Market Estimates and Projections by Region
12.1.1 Global Candidiasis Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Candidiasis Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Candidiasis Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Candidiasis Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Candidiasis Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Candidiasis Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Candidiasis Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Candidiasis Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Candidiasis Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Candidiasis Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Candidiasis Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Candidiasis Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Candidiasis Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Candidiasis Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Candidiasis Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Candidiasis Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Candidiasis Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Candidiasis Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Candidiasis Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Candidiasis Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Candidiasis Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Candidiasis Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Candidiasis Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Candidiasis Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Candidiasis Therapeutics Market Segments
Table 2. Ranking of Global Top Candidiasis Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Candidiasis Therapeutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Doxorubicin
Table 5. Major Manufacturers of Cisplatin
Table 6. Major Manufacturers of 7Carboplatin
Table 7. Major Manufacturers of Etoposide
Table 8. Major Manufacturers of Ifosfamide
Table 9. Major Manufacturers of Cyclophosphamide
Table 10. Major Manufacturers of Methotrexate
Table 11. Major Manufacturers of Vincristine
Table 12. Global Candidiasis Therapeutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 13. Global Candidiasis Therapeutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 14. Global Candidiasis Therapeutics Sales by Regions 2015-2020 (K Pcs)
Table 15. Global Candidiasis Therapeutics Sales Market Share by Regions (2015-2020)
Table 16. Global Candidiasis Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 17. Global Candidiasis Therapeutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 18. Global Candidiasis Therapeutics Sales Share by Manufacturers (2015-2020)
Table 19. Global Candidiasis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 20. Global Candidiasis Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Candidiasis Therapeutics as of 2019)
Table 21. Candidiasis Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 22. Candidiasis Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 23. Key Manufacturers Candidiasis Therapeutics Price (2015-2020) (USD/Pcs)
Table 24. Candidiasis Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Candidiasis Therapeutics Product Type
Table 26. Date of International Manufacturers Enter into Candidiasis Therapeutics Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 29. Global Candidiasis Therapeutics Sales Share by Type (2015-2020)
Table 30. Global Candidiasis Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 31. Global Candidiasis Therapeutics Revenue Share by Type (2015-2020)
Table 32. Candidiasis Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 33. Global Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 34. Global Candidiasis Therapeutics Sales Share by Application (2015-2020)
Table 35. North America Candidiasis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 36. North America Candidiasis Therapeutics Sales Market Share by Country (2015-2020)
Table 37. North America Candidiasis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 38. North America Candidiasis Therapeutics Revenue Market Share by Country (2015-2020)
Table 39. North America Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 40. North America Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Table 41. North America Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 42. North America Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Table 43. Europe Candidiasis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 44. Europe Candidiasis Therapeutics Sales Market Share by Country (2015-2020)
Table 45. Europe Candidiasis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 46. Europe Candidiasis Therapeutics Revenue Market Share by Country (2015-2020)
Table 47. Europe Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 48. Europe Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Table 49. Europe Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 50. Europe Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Table 51. Asia Pacific Candidiasis Therapeutics Sales by Region (2015-2020) (K Pcs)
Table 52. Asia Pacific Candidiasis Therapeutics Sales Market Share by Region (2015-2020)
Table 53. Asia Pacific Candidiasis Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 54. Asia Pacific Candidiasis Therapeutics Revenue Market Share by Region (2015-2020)
Table 55. Asia Pacific Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 56. Asia Pacific Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Table 57. Asia Pacific Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 58. Asia Pacific Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Table 59. Latin America Candidiasis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 60. Latin America Candidiasis Therapeutics Sales Market Share by Country (2015-2020)
Table 61. Latin Americaa Candidiasis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 62. Latin America Candidiasis Therapeutics Revenue Market Share by Country (2015-2020)
Table 63. Latin America Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 64. Latin America Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Table 65. Latin America Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 66. Latin America Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Table 67. Middle East and Africa Candidiasis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 68. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Country (2015-2020)
Table 69. Middle East and Africa Candidiasis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 70. Middle East and Africa Candidiasis Therapeutics Revenue Market Share by Country (2015-2020)
Table 71. Middle East and Africa Candidiasis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 72. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Table 73. Middle East and Africa Candidiasis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 74. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Table 75. Novartis AG Corporation Information
Table 76. Novartis AG Description and Major Businesses
Table 77. Novartis AG Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Novartis AG Product
Table 79. Novartis AG Recent Development
Table 80. Amgen Corporation Information
Table 81. Amgen Description and Major Businesses
Table 82. Amgen Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Amgen Product
Table 84. Amgen Recent Development
Table 85. F. Hoffmann-La Roche Ltd. Corporation Information
Table 86. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 87. F. Hoffmann-La Roche Ltd. Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. F. Hoffmann-La Roche Ltd. Product
Table 89. F. Hoffmann-La Roche Ltd. Recent Development
Table 90. Bayer-Algeta Corporation Information
Table 91. Bayer-Algeta Description and Major Businesses
Table 92. Bayer-Algeta Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Bayer-Algeta Product
Table 94. Bayer-Algeta Recent Development
Table 95. Merrion Pharmaceuticals Plc. Corporation Information
Table 96. Merrion Pharmaceuticals Plc. Description and Major Businesses
Table 97. Merrion Pharmaceuticals Plc. Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Merrion Pharmaceuticals Plc. Product
Table 99. Merrion Pharmaceuticals Plc. Recent Development
Table 100. Ablynx Corporation Information
Table 101. Ablynx Description and Major Businesses
Table 102. Ablynx Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Ablynx Product
Table 104. Ablynx Recent Development
Table 105. Genta Incorporated Corporation Information
Table 106. Genta Incorporated Description and Major Businesses
Table 107. Genta Incorporated Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Genta Incorporated Product
Table 109. Genta Incorporated Recent Development
Table 110. Galapagos NV Corporation Information
Table 111. Galapagos NV Description and Major Businesses
Table 112. Galapagos NV Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Galapagos NV Product
Table 114. Galapagos NV Recent Development
Table 115. Catena Pharmaceuticals Inc. Corporation Information
Table 116. Catena Pharmaceuticals Inc. Description and Major Businesses
Table 117. Catena Pharmaceuticals Inc. Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Catena Pharmaceuticals Inc. Product
Table 119. Catena Pharmaceuticals Inc. Recent Development
Table 120. Digna Biotech S.L. Corporation Information
Table 121. Digna Biotech S.L. Description and Major Businesses
Table 122. Digna Biotech S.L. Candidiasis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Digna Biotech S.L. Product
Table 124. Digna Biotech S.L. Recent Development
Table 125. Medivir AB Corporation Information
Table 126. Medivir AB Description and Major Businesses
Table 127. Medivir AB Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Medivir AB Product
Table 129. Medivir AB Recent Development
Table 130. Amura Holdings Corporation Information
Table 131. Amura Holdings Description and Major Businesses
Table 132. Amura Holdings Candidiasis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Amura Holdings Product
Table 134. Amura Holdings Recent Development
Table 135. Global Candidiasis Therapeutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 136. Global Candidiasis Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 137. Global Candidiasis Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 138. Global Candidiasis Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 139. North America: Candidiasis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 140. North America: Candidiasis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Europe: Candidiasis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 142. Europe: Candidiasis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Asia Pacific: Candidiasis Therapeutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 144. Asia Pacific: Candidiasis Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 145. Latin America: Candidiasis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 146. Latin America: Candidiasis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Middle East and Africa: Candidiasis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 148. Middle East and Africa: Candidiasis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 150. Key Challenges
Table 151. Market Risks
Table 152. Main Points Interviewed from Key Candidiasis Therapeutics Players
Table 153. Candidiasis Therapeutics Customers List
Table 154. Candidiasis Therapeutics Distributors List
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources
List of Figures
Figure 1. Candidiasis Therapeutics Product Picture
Figure 2. Global Candidiasis Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. Doxorubicin Product Picture
Figure 4. Cisplatin Product Picture
Figure 5. 7Carboplatin Product Picture
Figure 6. Etoposide Product Picture
Figure 7. Ifosfamide Product Picture
Figure 8. Cyclophosphamide Product Picture
Figure 9. Methotrexate Product Picture
Figure 10. Vincristine Product Picture
Figure 11. Global Candidiasis Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 12. Multispecialty Hospitals
Figure 13. Cancer Research Institutes
Figure 14. Others
Figure 15. Candidiasis Therapeutics Report Years Considered
Figure 16. Global Candidiasis Therapeutics Market Size 2015-2026 (US$ Million)
Figure 17. Global Candidiasis Therapeutics Sales 2015-2026 (K Pcs)
Figure 18. Global Candidiasis Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Candidiasis Therapeutics Sales Market Share by Region (2015-2020)
Figure 20. Global Candidiasis Therapeutics Sales Market Share by Region in 2019
Figure 21. Global Candidiasis Therapeutics Revenue Market Share by Region (2015-2020)
Figure 22. Global Candidiasis Therapeutics Revenue Market Share by Region in 2019
Figure 23. Global Candidiasis Therapeutics Sales Share by Manufacturer in 2019
Figure 24. The Top 10 and 5 Players Market Share by Candidiasis Therapeutics Revenue in 2019
Figure 25. Candidiasis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 26. Global Candidiasis Therapeutics Sales Market Share by Type (2015-2020)
Figure 27. Global Candidiasis Therapeutics Sales Market Share by Type in 2019
Figure 28. Global Candidiasis Therapeutics Revenue Market Share by Type (2015-2020)
Figure 29. Global Candidiasis Therapeutics Revenue Market Share by Type in 2019
Figure 30. Global Candidiasis Therapeutics Market Share by Price Range (2015-2020)
Figure 31. Global Candidiasis Therapeutics Sales Market Share by Application (2015-2020)
Figure 32. Global Candidiasis Therapeutics Sales Market Share by Application in 2019
Figure 33. Global Candidiasis Therapeutics Revenue Market Share by Application (2015-2020)
Figure 34. Global Candidiasis Therapeutics Revenue Market Share by Application in 2019
Figure 35. North America Candidiasis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 36. North America Candidiasis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 37. North America Candidiasis Therapeutics Sales Market Share by Country in 2019
Figure 38. North America Candidiasis Therapeutics Revenue Market Share by Country in 2019
Figure 39. U.S. Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. U.S. Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Canada Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 42. Canada Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. North America Candidiasis Therapeutics Market Share by Type in 2019
Figure 44. North America Candidiasis Therapeutics Market Share by Application in 2019
Figure 45. Europe Candidiasis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 46. Europe Candidiasis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Candidiasis Therapeutics Sales Market Share by Country in 2019
Figure 48. Europe Candidiasis Therapeutics Revenue Market Share by Country in 2019
Figure 49. Germany Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. Germany Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. France Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. U.K. Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Italy Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 58. Russia Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Europe Candidiasis Therapeutics Market Share by Type in 2019
Figure 60. Europe Candidiasis Therapeutics Market Share by Application in 2019
Figure 61. Asia Pacific Candidiasis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 62. Asia Pacific Candidiasis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Candidiasis Therapeutics Sales Market Share by Region in 2019
Figure 64. Asia Pacific Candidiasis Therapeutics Revenue Market Share by Region in 2019
Figure 65. China Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. China Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. Japan Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. South Korea Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. India Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Australia Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Taiwan Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Indonesia Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Thailand Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Malaysia Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Philippines Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 86. Vietnam Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Asia Pacific Candidiasis Therapeutics Market Share by Type in 2019
Figure 88. Asia Pacific Candidiasis Therapeutics Market Share by Application in 2019
Figure 89. Latin America Candidiasis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 90. Latin America Candidiasis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Candidiasis Therapeutics Sales Market Share by Country in 2019
Figure 92. Latin America Candidiasis Therapeutics Revenue Market Share by Country in 2019
Figure 93. Mexico Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Mexico Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Brazil Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 98. Argentina Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Latin America Candidiasis Therapeutics Market Share by Type in 2019
Figure 100. Latin America Candidiasis Therapeutics Market Share by Application in 2019
Figure 101. Middle East and Africa Candidiasis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 102. Middle East and Africa Candidiasis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 103. Middle East and Africa Candidiasis Therapeutics Sales Market Share by Country in 2019
Figure 104. Middle East and Africa Candidiasis Therapeutics Revenue Market Share by Country in 2019
Figure 105. Turkey Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Turkey Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Saudi Arabia Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. Saudi Arabia Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. U.A.E Candidiasis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 110. U.A.E Candidiasis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Middle East and Africa Candidiasis Therapeutics Market Share by Type in 2019
Figure 112. Middle East and Africa Candidiasis Therapeutics Market Share by Application in 2019
Figure 113. North America Candidiasis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. North America Candidiasis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Europe Candidiasis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Europe Candidiasis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Asia Pacific Candidiasis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Asia Pacific Candidiasis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Latin America Candidiasis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Latin America Candidiasis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Middle East and Africa Candidiasis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 122. Middle East and Africa Candidiasis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Porter's Five Forces Analysis
Figure 124. Channels of Distribution
Figure 125. Distributors Profiles
Figure 126. Bottom-up and Top-down Approaches for This Report
Figure 127. Data Triangulation
Figure 128. Key Executives Interviewed
血友病A・B治療材料の世界市場（～2026年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. Novel treatments for people suffering from hemophilia and other different bleeding problems h…- 犬インフルエンザ治療薬の世界市場（～2026年） Canine flu, which is also called dog flu; is a contagious disease that affects the dog’s respiratory system. It is mainly caused by canine influenza virus/Type An influenza virus. There are two types of influenza viruses H3N2 virus H3N8 virus. Market Analysis and Insights: Global Canine Flu Therapeu…
- 全身性乾癬治療薬の世界市場（～2026年） Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth. Factors that can trigger psoriasis include infections, heavy alcoho…
- 痛風治療薬の世界市場（～2026年） Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries. Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to …
- 淋病治療薬の世界市場（～2026年） Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep…